Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data
European Journal of Haematology · 2023
DOI: 10.1111/ejh.13969 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift European Journal of Haematology, 2023. Verfasst von Jens Panse und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Swedish Orphan Biovitrum.
Abstract (Originalsprache)
Objectives
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, non‐malignant haematological disorder associated with disabling fatigue and reduced health‐related quality of life. Post hoc analysis of PEGASUS phase 3 trial (NCT03500549) characterised improvements in patient‐reported fatigue measured by functional assessment of chronic illness therapy‐fatigue (FACIT‐fatigue) instrument item‐level ratings for pegcetacoplan and eculizumab for the treatment of PNH.
Methods
Item‐level responder analysis was conducted on a ≥2‐level change from baseline (CFB) clinically important response (CIR) for the FACIT‐fatigue 13 individual items rated on a 5‐level Likert scale. We evaluated ≥2‐level change against the minimal clinically important difference (MCID) of the FACIT‐fatigue total score (≥5 points) and clinical parameters, haemoglobin (Hb; ≥1 g/dL) and normalised absolute reticulocyte count (ARC; 30–100 pg/cells). Logistic regressions estimated baseline‐to‐Week‐16 FACIT‐fatigue item‐level transitional probabilities; Kaplan–Meier analysis estimated time to FACIT‐fatigue item CIR.
Results
Pegcetacoplan versus eculizumab was associated with significantly greater odds of Week 16 CIR across 8/13 items and on total score MCID (OR [CI] = 11.19 [3.73, 33.57]) and faster times to responses. The item‐level CIR threshold also showed clinical relevance on Hb level and ARC normalization.
Conclusions
Compared with eculizumab, pegcetacoplan was associated with clinically meaningful greater improvements on a majority of FACIT‐fatigue items.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Hematology, Hemostaseology and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
- Center for Integrated Oncology Aachen, Bonn, Cologne, Duesseldorf (CIO ABCD), Aachen, Germany.
- Swedish Orphan Biovitrum AB, Stockholm, Sweden.
- Apellis Pharmaceuticals, Inc., Waltham, Massachusetts, USA.
- Assignity Sp. z O.O., Krakow, Poland.
- Putnam Associates, Krakow, Poland.
ORCID-Profile: Jens Panse
Förderung
- Swedish Orphan Biovitrum
Zitieren
APA
Panse, J., Wilson, K., Fishman, J., Wojciechowski, P., Wdowiak, M., Horneff, R., Patriquin, C. J., Oliver, M., & Hakimi, Z. (2023). Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal of Haematology. https://doi.org/10.1111/ejh.13969
Vancouver
Panse J, Wilson K, Fishman J, Wojciechowski P, Wdowiak M, Horneff R, et al. Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data. European Journal of Haematology. 2023. doi:10.1111/ejh.13969
BibTeX
@article{Panse2023,
author = {Panse, Jens and Wilson, Koo and Fishman, Jesse and Wojciechowski, Piotr and Wdowiak, Marlena and Horneff, Regina and Patriquin, Christopher J and Oliver, Monika and Hakimi, Zalmai},
title = {Fatigue and health‐related quality of life in paroxysmal nocturnal haemoglobinuria: A post hoc analysis of the pegcetacoplan PEGASUS trial data},
journal = {European Journal of Haematology},
year = {2023},
doi = {10.1111/ejh.13969}
}
EUVIMED